Previous 10 | Next 10 |
EMERYVILLE, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018, after the market clo...
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, President and CEO, will provide a corporate update at the 8 th Annual SVB Leerink Global Healthcare C...
EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) and ...
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 61 Performance Each week, since the beginning of June 2017, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is ...
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices, Inc. (NASDAQ:AMD), Blackbaud, Inc. (NASDAQ:BLK...
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Intellia Therapeutics, Inc. (...
Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo Clinically Meaningful Reduction in Convulsive Seizure Frequency for FINTEPLA Maintained Ov...
Data Presented During Late-Breaker Session at 72 nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company de...
AGO , AL , ALTR , AMBR , AMC , AMPH , AQN , ARRS , ASRT , ATVI , BOJA , BPI , BRS , BW , CBPX , COLD , COLL , CTL , CYRX , DBX , DIS , DOX , ECOM , EGAN , EPAY , ERI , FGEN , FOE , FSCT , FSM , FTCH , GMED , HDP , HTZ , ICUI , JAG , JJSF , LGF.A , LOPE...
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...